200,000+ products from a single source!
sales@angenechem.com
204318-14-9 | L-Cysteinamide, N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide
CAS No: 204318-14-9 Catalog No: AG0029FD MDL No:
Product Description
Catalog Number:
AG0029FD
Chemical Name:
L-Cysteinamide, N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide
CAS Number:
204318-14-9
Molecular Formula:
C65H92N14O18S2
Molecular Weight:
1421.6390
IUPAC Name:
2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
InChI:
InChI=1S/C65H92N14O18S2/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90)/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+/m1/s1
InChI Key:
RZHKDBRREKOZEW-AAXZNHDCSA-N
SMILES:
NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC1=O)C(O)C)C(=O)N[C@@H]([C@H](O)C)CO)NC(=O)[C@@H](Cc1ccccc1)NC(=O)CN1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O)Cc1c[nH]c2c1cccc2
UNII:
U194AS08HZ
Properties
Complexity:
2620
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
10
Defined Bond Stereocenter Count:
0
Exact Mass:
1420.616g/mol
Formal Charge:
0
Heavy Atom Count:
99
Hydrogen Bond Acceptor Count:
25
Hydrogen Bond Donor Count:
17
Isotope Atom Count:
0
Molecular Weight:
1421.651g/mol
Monoisotopic Mass:
1420.616g/mol
Rotatable Bond Count:
26
Topological Polar Surface Area:
531A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-7.2
Literature
| Title | Journal |
|---|---|
| Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20130101 |
| Long-term evaluation of TiO2-based 68Ge/68Ga generators and optimized automation of [68Ga]DOTATOC radiosynthesis. | Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20121001 |
| A man with abdominal pain: enough evidence for surgery? | Clinical chemistry 20120801 |
| Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide. | Cancer 20120601 |
| Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc. | Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20120601 |
| Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. | Radiology 20120401 |
| Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. | European radiology 20120201 |
| What will be required to bring ⁶⁸Ga-labelled peptides into routine clinical use? | Nuclear medicine communications 20111201 |
| Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. | Endocrine-related cancer 20111001 |
| Personnel exposure in labelling and administration of (177)Lu-DOTA-D-Phe1-Tyr3-octreotide. | Nuclear medicine communications 20111001 |
| [Neuroendocrine pulmonary neoplasms: improved diagnosis by DOTATOC- vs. FDG-PET/CT]. | Pneumologie (Stuttgart, Germany) 20111001 |
| Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701 |
| (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. | Seminars in nuclear medicine 20110701 |
| Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. | Cancer 20110401 |
| Carcinoid tumor metastatic to the tarsal conjunctivae. | Ophthalmic plastic and reconstructive surgery 20110101 |
| Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110101 |
| Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. | Cancer imaging : the official publication of the International Cancer Imaging Society 20110101 |
| A matter of the heart: myocardial metastases in neuroendocrine tumors. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20101201 |
| Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy. | Molecular imaging 20101201 |
| Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids. | The Korean journal of internal medicine 20101201 |
| The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. | Annals of surgery 20101101 |
| Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20100801 |
| Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100701 |
| Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. | Clinical nuclear medicine 20100501 |
| Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. | European review for medical and pharmacological sciences 20100401 |
| Impurity in (68)Ga-peptide preparation using processed generator eluate. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20100301 |
| Role of 68Ga-DOTATOC PET/CT in carcinoids. | Pathology international 20100201 |
| Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT. | Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20100101 |
| Perspectives in the development of novel treatment approaches. | Tumori 20100101 |
| Novel use of somatostatin receptor scintigraphy in localization of focal congenital hyperinsulinism: promising but fallible. | Journal of pediatric endocrinology & metabolism : JPEM 20091001 |
| Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. | European journal of nuclear medicine and molecular imaging 20090901 |
| Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors. | Annals of nuclear medicine 20090801 |
| Synthesis and quality control of 68Ga citrate for routine clinical PET. | Nuclear medicine communications 20090701 |
| [Peptide receptor radionuclide therapy of neuroendocrine tumors]. | Ugeskrift for laeger 20090323 |
| Modeling combined radiopharmaceutical therapy: a linear optimization framework. | Technology in cancer research & treatment 20090201 |
| Positron emission tomography (PET) and macromolecular delivery in vivo. | Methods in molecular biology (Clifton, N.J.) 20090101 |
| Ga-68 DOTATOC PET/CT changed the therapeutic course of a patient with the sudden onset of vision problems. | Clinical nuclear medicine 20090101 |
| Imaging of somatostatin receptor subtype 2 in advanced hepatocellular carcinoma by 68Ga-DOTATOC PET. | Nuklearmedizin. Nuclear medicine 20090101 |
| [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations]. | Nuklearmedizin. Nuclear medicine 20090101 |
| [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. | Radiation oncology (London, England) 20090101 |
| Combination of (18)-FDG and (68)Ga-DOTATOC PET-CT to differentiate endobronchial carcinoids and inflammatory myofibroblastic tumors. | Journal of postgraduate medicine 20090101 |
| 68Ga-DOTATOC-PET/CT detects neuroendocrine differentiation of prostate cancer metastases. | Nuklearmedizin. Nuclear medicine 20090101 |
| Intraoperative identification of a neuroendocrine tumour diagnosed by 68Ga-DOTATOC PET but undetectable by surgical palpation or conventional imaging. | Nuklearmedizin. Nuclear medicine 20090101 |
| Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. | The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 20081201 |
| Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children. | Cancer metastasis reviews 20081201 |
| The importance of high specific radioactivity in the performance of 68Ga-labeled peptide. | Nuclear medicine and biology 20080701 |
| Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080601 |
| Retrospective analysis of radiation load during examination of cancer patients by (68)Ga-DOTATOC and (18)F-FDG positron emission tomography. | Bulletin of experimental biology and medicine 20080501 |
| Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. | Nuclear medicine communications 20080301 |
| 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20070401 |
| Neuroendocrine tumors. Peptide receptor radionuclide therapy. | Best practice & research. Clinical endocrinology & metabolism 20070301 |
| Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. | Cancer biotherapy & radiopharmaceuticals 20070201 |
| Reducing renal uptake of 111In-DOTATOC: a comparison among various basic amino acids. | Annals of nuclear medicine 20070101 |
| Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. | Surgery 20061201 |
| Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. | International journal of radiation oncology, biology, physics 20060501 |
| Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20060401 |
| A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors. | The Journal of veterinary medical science 20060401 |
| Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20051201 |
| Palliative management strategies of advanced gastrointestinal carcinoid neoplasms. | Langenbeck's archives of surgery 20050901 |
| Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20050501 |
| N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. | Journal of medicinal chemistry 20050421 |
| NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide. | Journal of medicinal chemistry 20050310 |
| Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. | Cancer 20050215 |
| A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. | Cancer biotherapy & radiopharmaceuticals 20050201 |
| Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20050101 |
| Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20050101 |
| Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. | European journal of nuclear medicine and molecular imaging 20041001 |
| A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. | European journal of nuclear medicine and molecular imaging 20040901 |
| Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial. | Lung cancer (Amsterdam, Netherlands) 20040901 |
| Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. | European journal of nuclear medicine and molecular imaging 20040701 |
| Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20040701 |
| A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20040701 |
| Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET. | European journal of nuclear medicine and molecular imaging 20040301 |
| Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment. | Cancer biotherapy & radiopharmaceuticals 20040201 |
| Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. | Cancer biotherapy & radiopharmaceuticals 20040201 |
| Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene. | Cancer biotherapy & radiopharmaceuticals 20040201 |
| Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. A Case Report. | Oncology 20040101 |
| Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. | Bioconjugate chemistry 20040101 |
| DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. | European journal of nuclear medicine and molecular imaging 20031001 |
| Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20031001 |
| 111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study. | European journal of nuclear medicine and molecular imaging 20030801 |
| Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases. | Cancer biotherapy & radiopharmaceuticals 20030801 |
| 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. | European journal of nuclear medicine and molecular imaging 20030401 |
| Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group. | British journal of cancer 20030310 |
| Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. | European journal of nuclear medicine and molecular imaging 20030201 |
| [Applications of somatostatin receptor scintigraphy in oncology: the need to incorporate SPECT into the imaging protocol]. | Revista espanola de medicina nuclear 20030101 |
| Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. | Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20030101 |
| 90Y-DOTATOC and nephrotoxicity. | European journal of nuclear medicine and molecular imaging 20021101 |
| Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals. | Nuclear medicine and biology 20020801 |
| Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl. | European journal of nuclear medicine and molecular imaging 20020801 |
| Optimization of the small-scale synthesis of DOTA-Tyr3 -octreotide. | Nuclear medicine communications 20020501 |
| Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20020501 |
| New advances in peptide receptor radionuclide therapy. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20020501 |
| Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. | European journal of nuclear medicine and molecular imaging 20020401 |
| Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe? | Medical science monitor : international medical journal of experimental and clinical research 20020401 |
| Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. | Seminars in nuclear medicine 20020401 |
| Is radiation nephropathy caused by yttrium-90? | Lancet (London, England) 20020316 |
| Kidney failure after treatment with 90Y-DOTATOC. | European journal of nuclear medicine and molecular imaging 20020301 |
| Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. | Nuclear medicine and biology 20020201 |
| Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. | European journal of nuclear medicine and molecular imaging 20020201 |
| 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. | Biopolymers 20020101 |
| Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. | European journal of nuclear medicine 20011201 |
| Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. | European journal of nuclear medicine 20011201 |
| Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC). | Swiss medical weekly 20011110 |
| End-stage renal disease after treatment with 90Y-DOTATOC. | European journal of nuclear medicine 20011001 |
| Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. | European journal of nuclear medicine 20011001 |
| PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20010701 |
| Somatostatin receptor imaging: current status and future perspectives. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20010701 |
| Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. | Thyroid : official journal of the American Thyroid Association 20010701 |
| The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. | Annals of oncology : official journal of the European Society for Medical Oncology 20010701 |
| Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. | Nuclear medicine communications 20010601 |
| A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20010401 |
| Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. | European journal of nuclear medicine 20010401 |
| The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. | Annals of oncology : official journal of the European Society for Medical Oncology 20010101 |
| Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. | Clinical cancer research : an official journal of the American Association for Cancer Research 19990501 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.